Corline Biomedical AB (CLBIO) - Net Assets

Latest as of September 2025: Skr77.23 Million SEK ≈ $8.31 Million USD

Based on the latest financial reports, Corline Biomedical AB (CLBIO) has net assets worth Skr77.23 Million SEK (≈ $8.31 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr82.31 Million ≈ $8.86 Million USD) and total liabilities (Skr5.09 Million ≈ $547.33K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CLBIO asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Skr77.23 Million
% of Total Assets	93.82%
Annual Growth Rate	41.3%
5-Year Change	67.04%
10-Year Change	309.0%
Growth Volatility	146.88

Corline Biomedical AB - Net Assets Trend (2012–2024)

This chart illustrates how Corline Biomedical AB's net assets have evolved over time, based on quarterly financial data. Also explore CLBIO asset base for the complete picture of this company's asset base.

Annual Net Assets for Corline Biomedical AB (2012–2024)

The table below shows the annual net assets of Corline Biomedical AB from 2012 to 2024. For live valuation and market cap data, see market value of Corline Biomedical AB.

Year	Net Assets	Change
2024-12-31	Skr86.91 Million ≈ $9.35 Million	-6.86%
2023-12-31	Skr93.32 Million ≈ $10.04 Million	-1.35%
2022-12-31	Skr94.59 Million ≈ $10.18 Million	+2.55%
2021-12-31	Skr92.23 Million ≈ $9.93 Million	+77.26%
2020-12-31	Skr52.03 Million ≈ $5.60 Million	-12.28%
2019-12-31	Skr59.32 Million ≈ $6.38 Million	+7.93%
2018-12-31	Skr54.96 Million ≈ $5.91 Million	+19.68%
2017-12-31	Skr45.93 Million ≈ $4.94 Million	+18.53%
2016-12-31	Skr38.75 Million ≈ $4.17 Million	+82.33%
2015-12-31	Skr21.25 Million ≈ $2.29 Million	+287.44%
2014-12-31	Skr5.48 Million ≈ $590.25K	-31.41%
2013-12-31	Skr8.00 Million ≈ $860.60K	+482.77%
2012-12-31	Skr1.37 Million ≈ $147.67K	--

Equity Component Analysis

This analysis shows how different components contribute to Corline Biomedical AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 13691840200.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Common Stock	Skr3.06 Million	3.52%
Other Comprehensive Income	Skr60.58 Million	69.71%
Other Components	Skr171.39 Million	197.19%
Total Equity	Skr86.91 Million	100.00%

Corline Biomedical AB Competitors by Market Cap

The table below lists competitors of Corline Biomedical AB ranked by their market capitalization.

Company	Market Cap
3U Holding AG XETRA:UUU	$42.34 Million
Entropy Neurodynamics Limited AU:ENP	$42.34 Million
Opnet Technologies Co Ltd TWO:8034	$42.34 Million
B&B Triplewall Containers Limited NSE:BBTCL	$42.43 Million
Vate Technology Co Ltd TWO:5344	$42.30 Million
Orient Paper & Industries Limited NSE:ORIENTPPR	$42.29 Million
Gigas Hosting S.A MC:GIGA	$42.29 Million
Johnson Matthey PLC LSE:JMAT	$42.28 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Corline Biomedical AB's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 93,316,000 to 86,914,000, a change of -6,402,000 (-6.9%).
Net loss of 23,194,000 reduced equity.
Share repurchases of 18,224,000 reduced equity.
New share issuances of 16,792,000 increased equity.
Other comprehensive income decreased equity by 2,495,000.
Other factors increased equity by 20,719,000.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	Skr-23.19 Million	-26.69%
Share Repurchases	Skr18.22 Million	-20.97%
Share Issuances	Skr16.79 Million	+19.32%
Other Comprehensive Income	Skr-2.50 Million	-2.87%
Other Changes	Skr20.72 Million	+23.84%
Total Change	Skr-	-6.86%

Book Value vs Market Value Analysis

This analysis compares Corline Biomedical AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 4.03x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 272.64x to 4.03x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2012-12-31	Skr0.06	Skr16.05	x
2013-12-31	Skr0.81	Skr16.05	x
2014-12-31	Skr0.55	Skr16.05	x
2015-12-31	Skr2.41	Skr16.05	x
2016-12-31	Skr3.20	Skr16.05	x
2017-12-31	Skr3.37	Skr16.05	x
2018-12-31	Skr3.53	Skr16.05	x
2019-12-31	Skr3.54	Skr16.05	x
2020-12-31	Skr3.03	Skr16.05	x
2021-12-31	Skr4.51	Skr16.05	x
2022-12-31	Skr4.40	Skr16.05	x
2023-12-31	Skr4.30	Skr16.05	x
2024-12-31	Skr3.98	Skr16.05	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Corline Biomedical AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -26.69%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -237.28%
• Asset Turnover: 0.10x
• Equity Multiplier: 1.09x
Recent ROE (-26.69%) is above the historical average (-28.23%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2012	-155.88%	-15.19%	0.48x	21.31x	Skr-969.94K
2013	-31.11%	-139.17%	0.13x	1.72x	Skr-3.29 Million
2014	-45.80%	-149.25%	0.10x	3.06x	Skr-3.06 Million
2015	-27.51%	-563.62%	0.04x	1.18x	Skr-7.97 Million
2016	-13.54%	-554.17%	0.02x	1.07x	Skr-9.12 Million
2017	-17.01%	-1224.14%	0.01x	1.12x	Skr-12.40 Million
2018	-12.36%	-434.61%	0.02x	1.14x	Skr-12.29 Million
2019	-16.08%	-896.62%	0.02x	1.07x	Skr-15.47 Million
2020	-14.00%	-197.16%	0.06x	1.12x	Skr-12.49 Million
2021	-7.50%	-97.93%	0.07x	1.10x	Skr-16.14 Million
2022	2.46%	9.89%	0.23x	1.08x	Skr-7.13 Million
2023	-1.94%	-7.23%	0.25x	1.07x	Skr-11.14 Million
2024	-26.69%	-237.28%	0.10x	1.09x	Skr-31.89 Million

Industry Comparison

This section compares Corline Biomedical AB's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $181,930,027
Average return on equity (ROE) among peers: -108.15%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Corline Biomedical AB (CLBIO)	Skr77.23 Million	-155.88%	0.07x	$42.30 Million
2cureX AB (2CUREX)	$8.19 Million	-5.85%	0.47x	$4.90 Million
Ascelia Pharma AB (publ) (ACE)	$236.06 Million	-41.81%	0.08x	$40.96 Million
AcouSort AB (ACOU)	$5.92 Million	-163.51%	0.36x	$8.97 Million
Active Biotech AB (ACTI)	$30.67 Million	-149.35%	0.44x	$17.19 Million
Alzinova AB (ALZ)	$947.42K	-195.83%	0.18x	$4.97 Million
AlzeCure Pharma (ALZCUR)	$32.97 Million	-235.89%	0.38x	$18.18 Million
Annexin Pharmaceuticals AB (ANNX)	$18.81 Million	-234.16%	0.42x	$11.24 Million
Alligator Bioscience AB (ATORX)	$115.24 Million	-124.61%	0.32x	$14.33 Million
BioInvent International AB (BINV)	$1.31 Billion	-25.22%	0.07x	$155.44 Million
BioArctic AB (publ) (BIOA-B)	$60.76 Million	94.77%	10.65x	$2.59 Billion

About Corline Biomedical AB

ST:CLBIO Sweden Biotechnology

Market Cap

$42.30 Million

Skr393.08 Million SEK

Market Cap Rank

#22495 Global

#416 in Sweden

Share Price

Skr16.05

Change (1 day)

-0.62%

52-Week Range

Skr9.66 - Skr21.20

All Time High

Skr28.20